Stephen Tyring

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial
    Stephen D Shafran
    Division of Infectious Diseases, Department of Medicine, 2E4 16 Walter C Mackenzie Health Sciences Centre, University of Alberta Hospital, 8440 112 Street, Edmonton, Alta, Canada T6G 2B7
    J Clin Virol 29:248-53. 2004
  2. ncbi request reprint Management of herpes zoster and postherpetic neuralgia
    Stephen K Tyring
    Department of Dermatology, The University of Texas, Houston, Texas, USA
    J Am Acad Dermatol 57:S136-42. 2007
  3. doi request reprint Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial
    Stephen K Tyring
    Departments of Dermatology, Microbiology and Molecular Genetics, and Internal Medicine, University of Texas Health Science Center, Houston, TX, USA
    J Med Virol 84:1224-32. 2012
  4. pmc Epidermodysplasia verruciformis and susceptibility to HPV
    Tejas Patel
    Center for Clinical Studies, University of Texas Health Science Center, Houston, TX, USA
    Dis Markers 29:199-206. 2010
  5. ncbi request reprint Single-day therapy for recurrent genital herpes
    Stephen Tyring
    Department of Dermatology, University of Texas Health Science Center, Houston, Texas 77058, USA
    Am J Clin Dermatol 7:209-11. 2006
  6. pmc Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes
    Stephen Tyring
    Department of Dermatology, Microbiology and Molecular Genetics and Internal Medicine, University of Texas Health Science Center, 2060 Space Park Drive, Suite 200, Houston, TX 77058, USA
    Arch Gynecol Obstet 275:1-3. 2007
  7. ncbi request reprint Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
    Stephen Tyring
    Department of Dermatology, The University of Texas Health Center at Houston, 6655 Travis, Suite 120, Houston, TX 77030, and Evanston Northwest Healthcare, Skokie, IL, USA
    Arch Dermatol 143:719-26. 2007
  8. doi request reprint Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older
    Anita Arora
    Department of Dermatology, University of Texas Houston School of Medicine, Houston, TX 77030, USA
    J Infect Dis 197:1289-95. 2008
  9. doi request reprint Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial
    Christopher M Hull
    Department of Dermatology, School of Medicine, University of Utah, Salt Lake City, Utah 84132 2409, USA
    J Am Acad Dermatol 64:696.e1-11. 2011
  10. doi request reprint Acquired epidermodysplasia verruciformis
    Heather D Rogers
    Department of Dermatology, Columbia University Medical Center, New York, New York, USA
    J Am Acad Dermatol 60:315-20. 2009

Research Grants

Detail Information

Publications77

  1. ncbi request reprint Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial
    Stephen D Shafran
    Division of Infectious Diseases, Department of Medicine, 2E4 16 Walter C Mackenzie Health Sciences Centre, University of Alberta Hospital, 8440 112 Street, Edmonton, Alta, Canada T6G 2B7
    J Clin Virol 29:248-53. 2004
    ....
  2. ncbi request reprint Management of herpes zoster and postherpetic neuralgia
    Stephen K Tyring
    Department of Dermatology, The University of Texas, Houston, Texas, USA
    J Am Acad Dermatol 57:S136-42. 2007
    ..There is a need for more effective agents to treat herpes zoster and postherpetic neuralgia...
  3. doi request reprint Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial
    Stephen K Tyring
    Departments of Dermatology, Microbiology and Molecular Genetics, and Internal Medicine, University of Texas Health Science Center, Houston, TX, USA
    J Med Virol 84:1224-32. 2012
    ..Nausea, headache, and vomiting were the most common adverse events. Based on these results, additional studies are warranted to define further EPB-348's potential as an effective and safe therapy for acute herpes zoster...
  4. pmc Epidermodysplasia verruciformis and susceptibility to HPV
    Tejas Patel
    Center for Clinical Studies, University of Texas Health Science Center, Houston, TX, USA
    Dis Markers 29:199-206. 2010
    ....
  5. ncbi request reprint Single-day therapy for recurrent genital herpes
    Stephen Tyring
    Department of Dermatology, University of Texas Health Science Center, Houston, Texas 77058, USA
    Am J Clin Dermatol 7:209-11. 2006
    ..In addition, the convenience of single-day treatment may lead to greater patient adherence and improved overall management of recurrent herpes outbreaks...
  6. pmc Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes
    Stephen Tyring
    Department of Dermatology, Microbiology and Molecular Genetics and Internal Medicine, University of Texas Health Science Center, 2060 Space Park Drive, Suite 200, Houston, TX 77058, USA
    Arch Gynecol Obstet 275:1-3. 2007
    ..Because single-day treatment is more convenient than traditional therapies, it may lead to improved patient compliance and better overall management of recurrent genital herpes outbreaks...
  7. ncbi request reprint Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
    Stephen Tyring
    Department of Dermatology, The University of Texas Health Center at Houston, 6655 Travis, Suite 120, Houston, TX 77030, and Evanston Northwest Healthcare, Skokie, IL, USA
    Arch Dermatol 143:719-26. 2007
    ..To evaluate the safety and efficacy of long-term treatment of psoriasis with etanercept, 50 mg twice weekly...
  8. doi request reprint Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older
    Anita Arora
    Department of Dermatology, University of Texas Houston School of Medicine, Houston, TX 77030, USA
    J Infect Dis 197:1289-95. 2008
    ..Participants in both arms of the study demonstrated similar median times to full crusting of the rash (8 days), and both dosages were safe and effective therapies for reduction of ZAP and ZAAS in the immunocompromised patient population...
  9. doi request reprint Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial
    Christopher M Hull
    Department of Dermatology, School of Medicine, University of Utah, Salt Lake City, Utah 84132 2409, USA
    J Am Acad Dermatol 64:696.e1-11. 2011
    ..ME-609 (Xerese, Xerclear) is a combination of 5% acyclovir and 1% hydrocortisone developed for the topical treatment of HSL...
  10. doi request reprint Acquired epidermodysplasia verruciformis
    Heather D Rogers
    Department of Dermatology, Columbia University Medical Center, New York, New York, USA
    J Am Acad Dermatol 60:315-20. 2009
    ....
  11. ncbi request reprint Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study
    Whitney Lapolla
    Center for Clinical Studies, 451 N Texas Ave, Webster, TX 77598, USA
    Arch Dermatol 147:901-7. 2011
    ..To evaluate the efficacy of treatment with gabapentin plus valacyclovir hydrochloride for the prevention of postherpetic neuralgia in patients with acute herpes zoster...
  12. ncbi request reprint Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older
    Vandana K Madkan
    Department of Dermatology, University of Texas School of Medicine, Center for Clinical Studies, Houston, TX 77030, USA
    J Cutan Med Surg 11:89-98. 2007
    ..Valacyclovir HCl, the L-valyl ester of acyclovir, is an antiviral drug that is used to accelerate the resolution of the herpes zoster rash and associated pain and reduce the duration of postherpetic neuralgia...
  13. ncbi request reprint Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
    Stephen Tyring
    Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX, USA
    Lancet 367:29-35. 2006
    ..Psoriasis has substantial psychological and emotional effects. We assessed the effect of etanercept, an effective treatment for the clinical symptoms of psoriasis, on fatigue and symptoms of depression associated with the condition...
  14. doi request reprint ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study
    Stephen Tyring
    Department of Dermatology, University of Texas Health Science Center, Houston, TX, USA
    J Infect Dis 205:1100-10. 2012
    ..Current therapies for genital herpes have only partial efficacy. Helicase-primase inhibitors are novel, potent inhibitors of herpes simplex virus replication...
  15. ncbi request reprint Epidermodysplasia verruciformis and human papilloma virus
    Aron Gewirtzman
    Center for Clinical Studies, Houston, TX 77030, USA
    Curr Opin Infect Dis 21:141-6. 2008
    ..We focus on recent findings in genetics, highlight multiple viewpoints regarding the role of epidermodysplasia verruciformis-human papillomavirus in nonmelanoma skin cancer and other diseases, and discuss treatment strategies...
  16. pmc Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology
    Sapna Modi
    Baylor College of Medicine Houston, TX, USA
    Ther Clin Risk Manag 4:409-17. 2008
    ..Lastly, the reduced number of pills necessary for single versus multiple day therapy decreases the overall cost of treatment per episode, an important factor in modern-day healthcare...
  17. ncbi request reprint Mucocutaneous manifestations of Epstein-Barr virus infection
    Natalia Mendoza
    Center for Clinical Studies, Houston, Texas, USA
    Am J Clin Dermatol 9:295-305. 2008
    ..Since the immune system is critical in preventing the progression of EBV disease, the immunologic status of the patient plays a crucial role in the subsequent development of pathologies...
  18. ncbi request reprint Single-dose famciclovir for the treatment of herpes labialis
    Christopher Hull
    Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT 84132 2405, USA
    Curr Med Res Opin 22:1699-702. 2006
    ..The pharmacokinetic/pharmacodynamic profile of famciclovir suggests that it could be utilized for episodic treatment for immunocompetent individuals as well...
  19. ncbi request reprint Filariasis: diagnosis and treatment
    Natalia Mendoza
    Universidad El Bosque, Bogota, Colombia
    Dermatol Ther 22:475-90. 2009
    ..However, continued research on new drugs and vaccinations will be needed to control and reduce the microfilarial levels in the human population...
  20. doi request reprint Emerging drugs for complicated skin and skin-structure infections
    Natalia Mendoza
    Center for Clinical Studies, 6655 Travis Suite 120, Houston, TX 77030, USA
    Expert Opin Emerg Drugs 15:509-20. 2010
    ..The need for new antibiotics is evident and the effort to decrease antibiotic resistance is a world priority...
  21. doi request reprint Shingles vaccine
    C Beau Willison
    Center for Clinical Studies, 451 North Texas Avenue, Webster, Texas 77598, USA
    Expert Opin Biol Ther 10:631-8. 2010
    ..Inc.) is effective in preventing shingles in individuals 60 years of age and older and recommended by the Center for Disease Control's (CDC) Advisory Committee for Immunization Practices (ACIP)...
  22. ncbi request reprint Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial
    Brenda L Bartlett
    University of Texas Health Science Center, Houston, TX 77058, United States
    J Clin Virol 43:190-5. 2008
    ..Recurrent genital HSV outbreaks are common among those suffering from the disease. Antiviral medications taken as suppressive therapy can reduce the frequency of these recurrences and reduce viral shedding occurring in between recurrences...
  23. doi request reprint Safety and efficacy of vaccines
    Brenda L Bartlett
    Center for Clinical Studies, University of Texas Health Science Center, Houston, Texas, USA
    Dermatol Ther 22:97-103. 2009
    ..In the future, it is anticipated that safe and effective vaccines will be developed against a number of other viral and bacterial infections as well as fungal and protozoan diseases...
  24. doi request reprint Vaccine immunology
    Brenda L Bartlett
    Center for Clinical Studies, University of Texas Health Sciences Health Science Center, Houston, Texas, USA
    Dermatol Ther 22:104-9. 2009
    ..These strains must have constant antigenic properties. A number of vaccine types exist, both traditional and innovative, and are described herein...
  25. doi request reprint Merkel cell polyomavirus detection in a patient with familial epidermodysplasia verruciformis
    Eun Kyung M Kwon
    Department of Dermatology, School of Medicine, University of Maryland, Baltimore, Maryland 21201, USA
    Pediatr Dermatol 30:505-7. 2013
    ..We report a case of Merkel cell polyomavirus detection in the skin of a patient with epidermodysplasia verruciformis (EDV) and a family history remarkable for an unusual inheritance pattern for EDV. ..
  26. doi request reprint Herpes zoster duplex bilateralis in an immunocompetent woman--is gender a risk factor?
    RACHEL GORDON
    Center for Clinical Studies, Houston, TX 77030, USA
    Popul Health Manag 15:398-400. 2012
    ..We present a case concerning herpes zoster duplex bilateralis occurring in a healthy, immunocompetent woman and discuss if female sex may be a risk factor for this presentation of herpes zoster...
  27. ncbi request reprint Valacyclovir for the treatment of genital herpes
    Julie S Brantley
    The University of Texas Medical Branch, Department of Dermatology, 301 University Boulevard, Galveston, TX 77555 0783, USA
    Expert Rev Anti Infect Ther 4:367-76. 2006
    ..The less frequent dosing regimen makes it an attractive option in the treatment of genital herpes and other viral infections, and may contribute to increased patient adherence to therapy...
  28. ncbi request reprint Recurrent genital herpes treatments and their impact on quality of life
    Mathijs H Brentjens
    Departments of Dermatology, Microbiology Immunology and Internal Medicine, University of Texas Medical Branch Galveston, Houston, Texas 77058, USA
    Pharmacoeconomics 21:853-63. 2003
    ..Newer therapeutic modalities, including the topical immune response modifier resiquimod and herpes vaccines, may eventually be shown to further decrease the psychological morbidity of recurrent genital herpes...
  29. ncbi request reprint Epidermodysplasia verruciformis in the setting of graft-versus-host disease
    Joy H Kunishige
    Department of Dermatology, University of Texas Health Science Center at Houston, Houston, Texas, USA
    J Am Acad Dermatol 57:S78-80. 2007
    ..Although EV-like lesions have been reported in patients who are immunocompromised, the incidence is low, and may be linked to EV-related haplotypes...
  30. ncbi request reprint Common variable immunodeficiency syndrome associated with epidermodysplasia verruciformis
    Jenny Vu
    Department of Dermatology, University of Texas MD Anderson Cancer Center and Medical School, Houston, Texas 77030 4009, USA
    Am J Clin Dermatol 8:307-10. 2007
    ..Our case is the second reported case of common variable immunodeficiency syndrome associated with EV...
  31. doi request reprint A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial
    Stephen Tyring
    Center for Clinical Studies, Department of Dermatology, University of Texas Health Science Center, Houston, TX, USA
    Int J Dermatol 49:1328-33. 2010
    ..0%) and the vehicle group (7.9%). The two-compound scalp formulation is safe and effective in the treatment of scalp psoriasis over 8 weeks in Hispanic/Latino and Black/African American patients...
  32. ncbi request reprint Managing herpes zoster in immunocompromised patients
    Ammar M Ahmed
    Baylor College of Medicine, Houston, TX, USA
    Herpes 14:32-6. 2007
    ..Appropriate analgesic therapy should be combined with early antiviral treatment to reduce the incidence and severity of acute zoster pain and post-herpetic neuralgia...
  33. ncbi request reprint Valacyclovir in the treatment of herpes simplex, herpes zoster, and other viral infections
    Jashin J Wu
    Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA
    J Cutan Med Surg 7:372-81. 2003
    ....
  34. ncbi request reprint Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs
    Tricia J Brown
    Department of Dermatology, Microbiology Immunology and Internal Medicine, University of Texas Medical Branch, Galveston 77555, USA
    J Am Acad Dermatol 47:581-99. 2002
    ..This review of antiviral agents discusses the treatments available for viral infections such as herpes simplex virus, varicella zoster virus, cytomegalovirus, human papillomavirus, chronic viral hepatitis, and others...
  35. ncbi request reprint Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review
    Elizabeth Y Chiao
    Baylor College of Medicine, Houston Center for Quality of Care and Utilization Studies, Health Services Research and Development Service, Michael E DeBakey Veterans Affairs Medical Center, TX, USA
    Clin Infect Dis 43:223-33. 2006
    ..This review identifies important areas for further study before routine anal Pap smear screening can be recommended...
  36. pmc Cutaneous phaeohyphomycosis caused by Paraconiothyrium cyclothyrioides
    Rachel A Gordon
    Center for Clinical Studies, Houston, Texas, USA
    J Clin Microbiol 50:3795-8. 2012
    ..cyclothyrioides. Treatment with posaconazole led to complete resolution of the lesions. P. cyclothyrioides should be considered an opportunistic human pathogen in immunocompromised patients...
  37. ncbi request reprint Ileostomy-associated chronic papillomatous dermatitis showing nevus sebaceous-like hyperplasia, HPV 16 infection, and lymphedema: a case report and literature review of ostomy-associated reactive epidermal hyperplasias
    Preethi Raghu
    Divisions of Dermatology and Dermatopathology, Albany Medical College, Albany, NY 12208, USA
    Am J Dermatopathol 34:e97-102. 2012
    ..We postulate that localized lymphedema secondary to scarring coupled with chronic epidermal irritation and inflammation allowed for latent HPV infection to manifest as CPD with NS-like cutaneous hyperplasia...
  38. ncbi request reprint Infection and panniculitis
    L Katie Morrison
    Department of Dermatology, University of Texas Health Sciences Center, Houston, Texas, USA
    Dermatol Ther 23:328-40. 2010
    ..Diagnosis and treatment are also discussed...
  39. doi request reprint Viremia in acute herpes zoster
    Anita K Satyaprakash
    Center for Clinical Studies, University of Texas Health Science Center, Houston, Texas, USA
    J Infect Dis 200:26-32. 2009
    ..A phase 2 trial was conducted to evaluate the efficacy of a topical antiviral, sorivudine, as an adjuvant to valacyclovir for the treatment of acute herpes zoster...
  40. ncbi request reprint Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses
    Jashin J Wu
    Department of Dermatology, University of California, Irvine, Irvine, CA, USA
    Antiviral Res 64:79-83. 2004
    ..Resiquimod shows promise for other viral infections and as a vaccine adjuvant...
  41. ncbi request reprint Vaccines for viral diseases with dermatologic manifestations
    Mathijs H Brentjens
    University of Texas Medical Branch Galveston, Department of Dermatology, Galveston, TX, USA
    Dermatol Clin 21:349-69. 2003
    ..Ongoing research shows promise in prophylactic and therapeutic vaccination for viral infections with cutaneous manifestations. Further studies are necessary before vaccines for HSV, HPV, and HIV become commercially available...
  42. doi request reprint Vaccines under study: non-HIV vaccines
    Kelly Conner
    The University of Texas Medical School, Houston, Texas 77030, USA
    Dermatol Ther 22:168-85. 2009
    ..This article focuses on vaccines that have yet to be approved for licensure...
  43. ncbi request reprint Current and potential uses of imiquimod
    Yuchi C Chang
    Department of Intemal Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    South Med J 98:914-20. 2005
    ..Common skin conditions that may be eradicated with imiquimod are emphasized...
  44. ncbi request reprint Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age
    Stephen K Tyring
    University of Texas Health Science Center, Houston, TX, USA
    Vaccine 25:1877-83. 2007
    ..This study of people >/= 50 or years of age compared the safety and tolerability of two zoster vaccine potencies...
  45. ncbi request reprint Changing paradigms in dermatology: antivirals in dermatology
    Peggy Lin
    Department of Dermatology, Northwestern University School of Medicine, Chicago, Illinois, USA
    Clin Dermatol 21:426-46. 2003
    ..Most of these antiviral drugs are virastatic and not viracidal. Vaccines and public health measures are much more effective and cost effective than antiviral drugs and must be promoted accordingly in the defense against viral infections...
  46. ncbi request reprint Selected sexually transmitted diseases and their relationship to HIV
    Jashin J Wu
    Department of Dermatology, University of California College of Medicine Irvine, Irvine, California, USA
    Clin Dermatol 22:499-508. 2004
    ....
  47. ncbi request reprint Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus
    Jeffrey M Weinberg
    Clinical Research Center, Department of Dermatology, St Luke s Roosevelt Hospital Center, NewYork, NY 10025, USA
    J Drugs Dermatol 9:1198-204. 2010
    ..aureus and Streptococcus pyogenes and may play an important role in limiting the development of resistance against systemic agents...
  48. ncbi request reprint Rickettsial infections around the world, part 1: pathophysiology and the spotted fever group
    Jashin J Wu
    Department of Dermatology, University of California, Irvine, California, USA
    J Cutan Med Surg 9:54-62. 2005
    ..These diseases are important to consider in endemic areas, but in certain suspicious cases, possible acts of bioterrorism should warrant prompt notification of the appropriate authorities...
  49. ncbi request reprint The management of herpes simplex virus infections
    Kimberly A Yeung-Yue
    Department of Dermatology, University of Texas Medical Branch Galveston, Galveston, Texas, USA
    Curr Opin Infect Dis 15:115-22. 2002
    ..However, immunologic advances in the treatment and prevention of herpes simplex infections are promising and continue to be studied...
  50. ncbi request reprint Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions
    Daniel Carrasco
    Department of Dermatology, University of Texas Medical Branch at Galveston, Texas, USA
    J Am Acad Dermatol 47:S212-6. 2002
    ..Therefore, treatment with imiquimod followed by excision of residual lesions may provide long-term clearance of anogenital warts in those patients in whom imiquimod monotherapy is insufficient...
  51. ncbi request reprint A review of antibiotics in dermatology
    Daniel A Carrasco
    Department of Dermatology, University of Texas Medical Branch Galveston, Galveston, Texas, USA
    J Cutan Med Surg 6:128-50. 2002
    ..Skin conditions from acne to leprosy, which were once shunned by society, are now easily treated with oral antibiotics...
  52. ncbi request reprint Advances in antiviral therapy
    Jashin J Wu
    Department of Dermatology, University of California at Irvine, 92697 2400, USA
    Dermatol Clin 23:313-22. 2005
    ..There are multiple vaccines available for certain viral diseases and others in development for HSV-2 and HPV...
  53. ncbi request reprint Treatment and prevention of rickettsial and ehrlichial infections
    Jennifer L Maender
    Department of Medicine, Christus St Joseph Hospital, Houston, TX, USA
    Dermatol Ther 17:499-504. 2004
    ..Human ehrlichiosis can present as monocytic ehrlichiosis or granulocytic anaplasmosis. Prevention is by avoidance of the responsible vectors. Therapy is usually with doxycycline, but chloramphenicol can also be used...
  54. ncbi request reprint Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations
    Jashin J Wu
    Center for Clinical Studies, Houston, Texas, USA
    J Am Acad Dermatol 50:495-528; quiz 529-32. 2004
    ..With this progress, it is hoped that effective vaccines soon will be developed for many more infectious diseases with cutaneous manifestations...
  55. ncbi request reprint Recommendations for the management of herpes zoster
    Robert H Dworkin
    Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, 14642, USA
    Clin Infect Dis 44:S1-26. 2007
    ..Specific recommendations for the use of these medications are provided. In addition, suggestions are made for treatments that, when used in combination with antiviral therapy, may further reduce pain and other complications of HZ...
  56. ncbi request reprint A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
    Mark Lebwohl
    Mt Sinai School of Medicine, New York 10029 6574, USA
    N Engl J Med 349:2004-13. 2003
    ..Efalizumab, a humanized monoclonal antibody, binds to the alpha subunit (CD11a) of LFA-1 and inhibits the activation of T cells...
  57. ncbi request reprint Once-daily valacyclovir to reduce the risk of transmission of genital herpes
    Lawrence Corey
    Department of Medicine, University of Washington, Seattle, USA
    N Engl J Med 350:11-20. 2004
    ..Nucleoside analogues against herpes simplex virus (HSV) have been shown to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent sexual transmission of HSV...
  58. ncbi request reprint Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial
    Karen E Mark
    Department of Medicine, University of Washington, Seattle, WA 98104, USA
    J Infect Dis 195:1324-31. 2007
    ..In animal models, induction of Th1-specific responses modifies experimental herpes simplex virus (HSV) infection...
  59. ncbi request reprint Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials
    Stephen K Tyring
    University of Texas Medical Branch, Galveston, USA
    J Cutan Med Surg 7:449-54. 2003
    ..Genital herpes is a very common sexually transmitted disease. Safe and effective therapies are needed for patients with frequent recurrences...
  60. ncbi request reprint Recent clinical experience with famciclovir--a "third generation" nucleoside prodrug
    Arun Chakrabarty
    Solano Research, Davis, Calif, USA
    Antivir Chem Chemother 15:251-3. 2004
    ..This short review points to recent experience with famciclovir in the management of HSV and varicella-zoster virus...
  61. ncbi request reprint Etanercept: an overview of its role in the treatment of psoriasis
    Malini Patel Galindo
    Center for Clinical Studies, 6655 Travis 120, Houston, TX 77030, USA
    Expert Opin Drug Metab Toxicol 4:305-10. 2008
    ..Psoriasis is a chronic and disabling disease affecting patients' quality of life...
  62. ncbi request reprint Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    Alan Menter
    Division of Dermatology, Baylor Research Institute, University of Texas Southwestern Medical School, 3900 Junius St, 125, Dallas, TX 75246 1613, USA
    J Am Acad Dermatol 58:106-15. 2008
    ..Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis...
  63. ncbi request reprint Demographic, behavioral, and knowledge factors associated with herpes simplex virus type 2 infection among men whose current female partner has genital herpes
    Rashida K Rana
    Worldwide Epidemiology, GlaxoSmithKline Research and Development, Greenford, U K
    Sex Transm Dis 32:308-13. 2005
    ..The objective of this study was to evaluate risk factors for herpes simplex virus type 2 (HSV-2) infection among men whose female partners have genital herpes (GH)...
  64. ncbi request reprint Herpes simplex viruses 1 and 2
    Kimberly A Yeung-Yue
    Departments of Dermatology, Microbiology Immunology, and Internal Medicine, University of Texas Medical Branch Galveston, Galveston, TX 77555, USA
    Dermatol Clin 20:249-66. 2002
    ..Newer treatments, such as resiquimod, actually may alter the course of HSV infection, reducing the severity and frequency of recurrences. Vaccines are being explored as preventive and therapeutic measures against HSV...
  65. ncbi request reprint A unique pattern of hyperhidrosis and herpes zoster
    Jashin J Wu
    Arch Dermatol 142:1069. 2006
  66. ncbi request reprint Viral and nonviral uses of imiquimod: a review
    Aditya K Gupta
    Division of Dermatology, Department of Medicine, Sunnybrook and Women s College Health Science Center, University of Toronto, Toronto, Ontario, Canada
    J Cutan Med Surg 8:338-52. 2004
    ..This drug has been recently approved for the treatment of actinic keratoses and superficial basal cell carcinoma. There is a growing body of evidence for its effectiveness in treating a variety of other skin conditions...
  67. ncbi request reprint Postherpetic poliosis
    Jashin J Wu
    Arch Dermatol 142:250-1. 2006
  68. ncbi request reprint A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects
    Guy de Bruyn
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Vaccine 24:914-20. 2006
    ..A replication incompetent herpes virus lacking the glycoprotein H gene has been developed as a potential therapeutic vaccine for genital herpes...
  69. ncbi request reprint Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine
    David I Bernstein
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA
    Clin Infect Dis 40:1271-81. 2005
    ....
  70. doi request reprint Family history as a risk factor for herpes zoster: a case-control study
    Lindsey D Hicks
    University of Texas Medical School at Houston, USA
    Arch Dermatol 144:603-8. 2008
    ..To assess risk factors for herpes zoster beyond age and immunosuppression, especially the association with a family history of herpes zoster, since a preventative herpes zoster and postherpetic neuralgia vaccine is now available...
  71. ncbi request reprint Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir
    Stephen K Tyring
    University of Texas Medical Branch, Galveston, Texas 77555, USA
    J Infect Dis 186:S40-6. 2002
    ..Extensive sensitivity monitoring of HSV isolates confirmed a very low rate of acyclovir resistance among immunocompetent subjects (<0.5%). The incidence of resistance among immunocompromised patients remains low at about 5%...
  72. ncbi request reprint Effect of imiquimod in anogenital warts from HIV-positive men
    Silvia Herrera
    GRID, Dermatology Section, Department of Internal Medicine, University of Antioquia, Medellin, Colombia
    J Clin Virol 39:210-4. 2007
    ..HIV-positive patients have unpredictable local immune responses even with severe systemic immunosuppression and data reported to date is insufficient to predict the effect of imiquimod in HIV-positive patients...
  73. ncbi request reprint Molluscum contagiosum: the importance of early diagnosis and treatment
    Stephen K Tyring
    UTMB Center for Clinical Studies, University of Texas Medical Branch, 301 University Boulevard, Route 1070, Galveston, TX 77555, USA
    Am J Obstet Gynecol 189:S12-6. 2003
    ..This review summarizes the clinical diagnosis of molluscum contagiosum and provides a critical assessment of several current and emerging treatment options...
  74. pmc Varicella-zoster virus in the saliva of patients with herpes zoster
    Satish K Mehta
    Enterprise Advisory Services, Inc, USA
    J Infect Dis 197:654-7. 2008
    ..Analysis of human saliva has potential usefulness in the diagnosis of neurological disease produced by VZV without rash...
  75. ncbi request reprint Emerging therapies for herpes viral infections (types 1 - 8)
    Arun Chakrabarty
    Solano Clinical Research, Davis, California, USA
    Expert Opin Emerg Drugs 9:237-56. 2004
    ..The new helicase primase inhibitors, which are the first non-nucleoside antiviral compounds, are being investigated for treatment of HSV disease, including infections resistant to existing therapy...
  76. doi request reprint Ustekinumab for chronic plaque psoriasis
    Brenda L Bartlett
    Center for Clinical Studies and Department of Dermatology, University of Texas Health Science Center, Houston, TX 77030, USA
    Lancet 371:1639-40. 2008
  77. ncbi request reprint Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience
    Richard G B Langley
    Dalhousie University, Halifax, Nova Scotia, Canada
    Clin Ther 27:1317-28. 2005
    ..Efalizumab is a biologic therapy targeted to inhibit T cells. Its efficacy has been shown in clinical trials encompassing >3500 patients with psoriasis...

Research Grants1

  1. Genetic Resistance to Oncogenic Human Papillomaviruses
    Stephen Tyring; Fiscal Year: 2004
    ..Thus, this study is an important step in the development of an HPV vaccine to prevent infection. ..